Eli Lilly (LLY)
(Delayed Data from NYSE)
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.35 -0.20 (-0.02%) 4:18 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.35 -0.20 (-0.02%) 4:18 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
Eli Lilly (LLY) Stock Moves -0.35%: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $149.02, marking a -0.35% move from the previous day.
AstraZeneca's Farxiga Betters Survival in Renal Outcome Study
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga significantly reduces the risk of kidney failure and cardiovascular or death in patients with chronic kidney disease.
Why Eli Lilly (LLY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Why Is Lilly (LLY) Down 3.7% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Workday (WDAY) Tops on Q2 Earnings & Revenues, Stock Rises
by Radhika Pujara
Workday's (WDAY) fiscal second-quarter results benefit from a high demand for its cloud-based HCM and financial management solutions, and synergies from the Scout RFP acquisition.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
United Therapeutics Announces FDA Acceptance of Tyvaso sNDA
by Zacks Equity Research
United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
by Kinjel Shah
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Top Stock Reports for Apple, Mastercard & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Eli Lilly (LLY).
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio
by Benjamin Rains
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi
by Zacks Equity Research
Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.